1Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126(3 Suppl): 338-400.
2Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): 9-16.
3Liew NC, Moissinac K, Gul Y. Postoperative venous thromboembolism in Asia: a critical appraisal of its incidence. Asian J Surg,2003, 26: 154-158.
4Geerts WH, Heir JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest, 2001, 119(1 Suppl): 132-175.
5Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med, 2002, 162: 1833-1840.
6Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg(Am), 2001, 83: 900-906.
7Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest, 2003, 124(6 Suppl): 386-392.
8O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med, 2003, 163:1362-1366.
9Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of lowmolecular-weight heparin with oral anticoagulant. Arch Intern Med,2002, 162: 2191-2196.
10AIDA: 45th American Society of Hematology Annual Meeting. San Diego, 2003.
